AmirAli Talasaz,
Co-Founder, President & COO,
Guardant Health
Dr. Amirali Talasaz, Ph.D. serves as the President and Chief Operating Officer of Guardant Health Inc. Mr. Talasaz is a serial entrepreneur in the sample preparation and clinical research fields. Prior to co-founding Guardant, he served as Senior Director of Diagnostics Research at Illumina and led the research efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different sample preparation technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on genetic analysis of circulating tumor cells for cancer management. Prior to his industrial career, he led the Technology Development group at Stanford Genome Technology Center. Mr. Talasaz received his PhD in Electrical Engineering and MSc in Management Science from Stanford University.
Clinical implications of genomic variants identified in over 30,000 advanced-stage cancer patients by next-generation sequencing of circulating tumor DNA
Friday, 6 October 2017 at 16:00
Add to Calendar ▼2017-10-06 16:00:002017-10-06 17:00:00Europe/LondonClinical implications of genomic variants identified in over 30,000 advanced-stage cancer patients by next-generation sequencing of circulating tumor DNALiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) enables non-invasive profiling of solid tumor cancers. Over the past few years, research and clinical practice guidelines have highlighted a role for liquid biopsy in patient care. In addition, liquid biopsies are becoming essential for successful patient enrollment in clinical trials, where tissue access and high rate of failures have been limiting factors slowing enrollment. In this talk, we characterize somatic genomic profiles derived from over 35,000 plasma samples from advanced cancer patients as were determined by a ctDNA NGS test targeting up to 73 genes (Guardant360®). Accuracy of ctDNA-detected driver alterations (PPV) was assessed by comparing to available matched tissue tests for 646 patients (lung, colon, and other cancer types). A pooled response rate analysis was performed across 11 published/pre-press datasets analyzing response to Guardant360®-directed therapy. Use of liquid biopsies is increasing in clinical care, providing an option of obtaining genomic information non-invasively. This dataset, derived from liquid biopsy use in clinical practice, highlights the clinical impact of identifying alterations that are targetable by drugs with regulatory approval, including emergent resistance alterations, as well as novel targets.
Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-10-06 16:00:002017-10-06 17:00:00Europe/LondonClinical implications of genomic variants identified in over 30,000 advanced-stage cancer patients by next-generation sequencing of circulating tumor DNALiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
_150x75.jpg)
.gif){kind=logo}
